HighLife
HighLife SAS, headquartered in Paris, France, with offices in Irvine (California), is an early-stage company established in 2010. It is focused on the development of a novel transcatheter replacement system for treating mitral regurgitation. The technology aims at a beating heart procedure reducing trauma to the patients.
Sector
Medical Devices
Strategy
Capital
Status
Live
Website
www.highlifemedical.com
Related News
HighLife granted US FDA Breakthrough Device Designation for its TMVR solution
HighLife receives ISO 13485 certification of its quality management system
HighLife welcomes Stefan Pilz as new Chief Executive Officer
HighLife receives IDE approval to initiate US pivotal clinical study for treatment of mitral regurgitation
HighLife appoints Prof. Stephen Brecker Chief Medical Officer
HighLife launches a new Large Annulus Valve in ongoing clinical studies for patients suffering from Mitral Regurgitation
Peijia Medical and HighLife Enter Into License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China
HighLife closes a €32 million round B financing
Highlife appoints Dr. Martin Rothman as independent member of the board
Highlife appoints Jose Calle Gordo as Chairman of the board
Highlife closes €12.3 million financing round led by Sofinnova Partners
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.